What AI Really Needs to Cure Diseases: Boring Policy Answers
scottleibrand · x · 2026-07-30
The article explores the real barriers AI faces in curing diseases. The author points out that while US law requires clinical trial results to be public—with a $10,000/day fine for non-compliance—the FDA has never actually collected these fines, leading to poor data adherence. The piece argues that unlocking AI's potential in medicine requires prioritizing these boring but critical policy and data barriers.
Related event: Industry Reflects on AI Drug Discovery Bottlenecks and Overpromises(2 posts)→
More from AGI Musings
- Looking Back at 3-Year-Old Predictions: AGI Might Arrive Before Binding Treaties — davidmanheim · 2026-07-30
- Huge bull market for AI-native ICs vs. bear market for traditional managers — gabepgomes · 2026-07-30
- SemiAnalysis Founder Rebuts AI Doom: The Future Holds More Jobs — dylan522p · 2026-07-30
- Why Are AI Safety Researchers Pessimistic? Ex-OpenAI Staffer Sparks Debate — DKokotajlo · 2026-07-30
- Biologist Michael Levin Argues Intelligence Originates from a Nonphysical Realm — voidwalker_com · 2026-07-30
- Palantir CEO Karp: AI Adoption Transfers Enterprise Alpha to Frontier Labs — r0ck3t23 · 2026-07-30